Signaling Pathways
-
BA2259 EnsitrelvirSummary: Ensitrelvir (S-217622) is the first to be orally active. -
BA2262 LP-935509Summary: LP-935509 is an orally potent, selective, ATP-competitive, and blood-brain barrier-crossing inhibitor of junctional protein-2-related kinase 1. - BA2263 MerafloxacinSummary: Merafloxacin (CI-934), a fluoroquinolone antimicrobial agent, is a selective programmed-1 ribosome translocation inhibitor of beta viruses.
- BA2265 PF-00835231Summary: PF-00835231 is an inhibitor of a major viral protease.
- BA2266 EnoxaparinSummary: Enoxaparin (PK10169) is a low molecular heparin (LMWH) derivative.
- BA2267 IbuzatrelvirSummary: Ibuzatrelvir (PF-07817883), second-generation oral bioavailability, is a SARS-CoV-2 major protease (and) inhibitor with improved metabolic stability.
- BA2269 GS-621763Summary: GS-621763 is an orally effective precursor to GS-441524.
- BA2270 PomotrelvirSummary: Pomotrelvir (PBI-0451) is a selective, orally active 3CL protease inhibitor.
- BA2271 Vps34-IN-2Summary: Vps34-IN-2 is a novel, potent and selective inhibitor.
- BA2272 CCF0058981Summary: CCF0058981 (CCF981) is a 3-chlorophenyl analog, a non-covalent inhibitor.